Merck & Co (NYSE: MRK) has been granted a new label update for its immuno-oncology blockbuster, Keytruda (pembrolizumab), in metastatic small cell lung cancer (SCLC).
Merck’s anti-PD-1 therapy has been given the green light to be marketed as monotherapy in the third-line setting, based on an accelerated approval.
The decision comes not long after the firm picked up an approval for the I-O option in Europe, for the first-line treatment of squamous non-small cell lung cancer (NSCLC), in combination with chemo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze